| Wang, Yi |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-Oļ¼recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
UplighTED, NCT06307626: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease. |
|
|
| Recruiting | 3 | 108 | Europe, Japan, US, RoW | Efgartigimod PH20 SC, Placebo PH20 SC | argenx | Thyroid Eye Disease | 02/26 | 10/27 | | |
| Active, not recruiting | 3 | 194 | Europe, Canada, Japan, US, RoW | Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo | Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc. | Immune Thrombocytopenia | 06/25 | 11/26 | | |
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma |
|
|
| Not yet recruiting | 3 | 83 | RoW | Nelarabine injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma | 12/25 | 05/26 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC). |
|
|
| Completed | 3 | 298 | Europe, Canada, US, RoW | NovoTTF-200M device, Best Standard of Care | NovoCure GmbH | Brain Metastases from Non-small Cell Lung Cancer (NSCLC) | 11/24 | 11/24 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05614531: Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1 |
|
|
| Enrolling by invitation | 1/2 | 12 | RoW | EXG001-307 injection | Hangzhou Jiayin Biotech Ltd | Spinal Muscular Atrophy Type I | 08/25 | 08/25 | | |
| Active, not recruiting | 1 | 160 | Europe, Canada, US | SL-172154, Azacitidine, Venetoclax | Shattuck Labs, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 11/24 | 11/24 | | |
NCT06588803: A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA |
|
|
| Not yet recruiting | N/A | 18 | NA | No intervention, only for observational studies | Hangzhou Jiayin Biotech Ltd | Spinal Muscular Atrophy | 09/30 | 12/30 | | |
| Pu, Yonglan |
NCT05755776: The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment |
|
|
| Recruiting | N/A | 204 | RoW | TMF, Heng Mu | The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Chronic Hepatitis B | 12/24 | 12/24 | | |
